ChiCTR2400081455 版本V1.0 版本创建时间2024/03/01 10:43:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400081455 

最近更新日期:

Date of Last Refreshed on:

2024-03-01 10:43:52 

注册时间:

Date of Registration:

2024-03-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

激光共聚焦显微内镜在膀胱癌早期诊断中的临床应用

Public title:

Clinical application of laser confocal microscopy in early diagnosis of bladder cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

激光共聚焦显微内镜在膀胱癌早期诊断中的临床应用

Scientific title:

Clinical application of laser confocal microscopy in early diagnosis of bladder cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周家合 

研究负责人:

韩从辉 

Applicant:

Jiahe Zhou 

Study leader:

Conghui Han 

申请注册联系人电话:

Applicant telephone:

+86 181 1200 7565

研究负责人电话:

Study leader's telephone:

+86 138 1346 1893

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jiaheac@163.com

研究负责人电子邮件:

Study leader's E-mail:

hanchdoctor@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省徐州市泉山区解放南路199号

研究负责人通讯地址:

江苏省徐州市泉山区解放南路199号

Applicant address:

199 Jiefang South Road, Quanshan District, Xuzhou City, Jiangsu Province

Study leader's address:

199 Jiefang South Road, Quanshan District, Xuzhou City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

徐州市中心医院

Applicant's institution:

Xuzhou Central Hospital

研究负责人所在单位:

徐州市中心医院

Affiliation of the Leader:

Xuzhou Central Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

XZXY-LK-20231212-0205

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

徐州市中心医院生物医学研究伦理审查委员会

Name of the ethic committee:

Biomedical Research Ethics Review Committee of Xuzhou Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-12-12 00:00:00

伦理委员会联系人:

吴计贫

Contact Name of the ethic committee:

Jipin Wu

伦理委员会联系地址:

徐州市大龙湖街道太行路29号

Contact Address of the ethic committee:

No. 29 Taihang Road, Dalonghu Street, Xuzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 516 8395 6765

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

徐州市中心医院

Primary sponsor:

Xuzhou Central Hospital

研究实施负责(组长)单位地址:

江苏省徐州市泉山区解放南路199号

Primary sponsor's address:

199 Jiefang South Road, Quanshan District, Xuzhou City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

徐州市

Country:

China

Province:

Jiangsu Province

City:

Xuzhou City

单位(医院):

徐州市中心医院

具体地址:

江苏省徐州市泉山区解放南路199号

Institution
hospital:

Xuzhou Central Hospital

Address:

199 Jiefang South Road, Quanshan District, Xuzhou City, Jiangsu Province

经费或物资来源:

课题经费,包括以下课题:江苏省社会发展重点项目BE2019637,江苏省社会发展重点项目BE2020758,徐州市科技计划重点项目KC19075

Source(s) of funding:

Project funding includes the following topics: Jiangsu Province Social Development Key Project BE2019637, Jiangsu Province Social Development Key Project BE2020758, and Xuzhou City Science and Technology Plan Key Project KC19075

Target disease:

Bladder cancer

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

1.使用激光共聚焦显微内镜在膀胱癌检查诊断中的应用; 2.探索激光共聚焦显微内镜进行膀胱镜检查的关键临床技术及要点。 3.研究激光共聚焦显微内镜在膀胱癌早期诊断中的临床意义,提高膀胱癌早期诊断率。  

Objectives of Study:

1. The application of laser confocal microscopy in the examination and diagnosis of bladder cancer; 2. Explore the key clinical techniques and key points of laser confocal microscopy for cystoscopy examination. 3. To study the clinical significance of laser confocal microscopy in the early diagnosis of bladder cancer and improve the early diagnosis rate of bladder cancer.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)反复血尿怀疑膀胱肿瘤的患者 (2)彩超或CT等影像学检查发现膀胱占位的患者 (3)膀胱癌术后随访检查的患者 (4)膀胱镜检查发现膀胱黏膜可疑病变的患者

Inclusion criteria

(1) Patients with recurrent hematuria suspected of bladder tumors (2) Patients with bladder masses detected through imaging examinations such as ultrasound or CT (3) Patients with postoperative follow-up examination of bladder cancer (4) Patients with suspicious lesions of bladder mucosa detected during cystoscopy examination

排除标准:

(1)膀胱镜检查禁忌的患者 (2)拒绝行激光共聚焦显微内镜检查的患者 (3)过敏体质的患者

Exclusion criteria:

(1) Patients contraindicated by cystoscopy examination (2) Patients who refuse to undergo laser confocal microscopy examination (3) Patients with allergic constitution

研究实施时间:

Study execute time:

From 2024-03-01 00:00:00 To 2025-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-03-04 00:00:00 To 2025-02-01 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

普通膀胱镜检查结果联合病理学诊断

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Combined results of conventional cystoscopy and pathological diagnosis

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

激光共聚焦显微内镜(LCME)联合普通膀胱镜(UB)

Index test:

Laser confocal microscopy endoscopy (LCME) combined with conventional cystoscopy (UB)

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

(1)反复血尿怀疑膀胱肿瘤的患者 (2)彩超或CT等影像学检查发现膀胱占位的患者 (3)膀胱癌术后随访检查的患者 (4)膀胱镜检查发现膀胱黏膜可疑病变的患者

例数:

Sample size:

100

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

(1) Patients with recurrent hematuria suspected of bladder tumors (2) Patients with bladder masses detected through imaging examinations such as ultrasound or CT (3) Patients with postoperative follow-up examination of bladder cancer (4) Patients with suspicious lesions of bladder mucosa detected during cystoscopy examination

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

None

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

徐州市 

Country:

China 

Province:

Jiangsu Province 

City:

Xuzhou City 

单位(医院):

徐州市中心医院 

单位级别:

三甲 

Institution
hospital:

Xuzhou Central Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

诊断灵敏度

指标类型:

主要指标

Outcome:

Diagnostic sensitivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

诊断特异度

指标类型:

主要指标

Outcome:

Diagnostic specificity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

漏诊率

指标类型:

次要指标

Outcome:

False negative rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后血尿

指标类型:

副作用指标

Outcome:

Postoperative hematuria

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿道疼痛

指标类型:

副作用指标

Outcome:

Urethral pain

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膀胱痉挛

指标类型:

副作用指标

Outcome:

Bladder spasms

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膀胱损伤

指标类型:

副作用指标

Outcome:

Injury of bladder

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

准确率

指标类型:

主要指标

Outcome:

Accuracy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

膀胱组织

组织:

Sample Name:

Bladder tissue

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表;符合条件的患者被随机分配到LCME+UB组或UB组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table; Eligible patients were randomly assigned to either the LCME+UB group or the UB group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-03-01 10:43:52